▲ +758.09% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Soleno Therapeutics in the last 3 months. The average price target is $8.67, with a high forecast of $10.00 and a low forecast of $8.00. The average price target represents a 758.09% upside from the last price of $1.01.
The current consensus among 3 investment analysts is to buy stock in Soleno Therapeutics. This Buy consensus rating has held steady for over two years.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.